All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
Introducing
Now you can personalise
your Multiple Myeloma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the Multiple Myeloma Hub spoke to Luca Bertamini, University of Turin, Turin, IT. We asked, Can we use circulating tumor cells to identify high-risk patients?
Can we use circulating tumor cells to identify high-risk patients?
Bertamini reports the data from a study aiming to identify the best cut-off for circulating plasma cells to predict progression-free survival and overall survival. Together with well-known baseline prognostic features, analyzing circulating plasma cells by flow cytometry could add some information to the risk evaluation.
Your opinion matters
Subscribe to get the best content related to multiple myeloma delivered to your inbox